Search Results - "Calandrino, Lucrezia"

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study by Mazzitelli, Maria, Mengato, Daniele, Sasset, Lolita, Ferrari, Anna, Gardin, Samuele, Scaglione, Vincenzo, Bonadiman, Nicola, Calandrino, Lucrezia, Cavinato, Silvia, Trivellato, Sabrina, Venturini, Francesca, Cattelan, Anna Maria

“…Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for the early treatment of COVID-19, but real-life data on tolerability, safety, and…”
Get full text

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern by Mazzaferri, Fulvia, Mirandola, Massimo, Savoldi, Alessia, De Nardo, Pasquale, Morra, Matteo, Tebon, Maela, Armellini, Maddalena, De Luca, Giulia, Calandrino, Lucrezia, Sasset, Lolita, D'Elia, Denise, Sozio, Emanuela, Danese, Elisa, Gibellini, Davide, Monne, Isabella, Scroccaro, Giovanna, Magrini, Nicola, Cattelan, Annamaria, Tascini, Carlo, Tacconelli, Evelina

“…Background: Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2…”
Get full text

Kaposi sarcoma and vertebral involvement in people with HIV: a case report and systematic literature review by Mazzitelli, Maria, Leoni, Davide, Maraolo, Alberto, Marinello, Serena, Calandrino, Lucrezia, Panese, Angela, Calabrò, Maria Luisa, Marino, Dario, Scaglione, Vincenzo, Cattelan, Annamaria

“…Kaposi Sarcoma (KS) has been historically associated with HIV, especially in people with advanced immunosuppression. Its prevalence decreased over time, but…”
Get full text

Risk of hospitalization and sequelae in patients with COVID‐19 treated with 3‐day early remdesivir vs. controls in the vaccine and Omicron era: A real‐life cohort study by Mazzitelli, Maria, Trunfio, Mattia, Sasset, Lolita, Scaglione, Vincenzo, Ferrari, Anna, Mengato, Daniele, Gardin, Samuele, Bonadiman, Nicola, Calandrino, Lucrezia, Agostini, Elena, Cattelan, Anna Maria

“…Recently, a benefit from administration of a 3‐day course of early remdesivir (ER) in the outpatients' setting was reported. However, real‐life data on its use…”
Get full text